Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology
| Autor: | Susanne Lemcke, Enno Schmidt, Snejina Vassileva, Ljiljana Medenica, Detlef Zillikens, Soner Uzun, Winfried Stöcker, Hana Jedličková, Kristin Rentzsch, Giovanni Di Zenzo, Shamir Geller, Aikaterini Patsatsi, Stephanie Goletz, Marian Dmochowski, Dedee F. Murrell, Cezary Kowalewski, Tarek Fuhrmann, Xue Jun Zhu, Kossara Drenovska, Stine Krüger, Christian Probst, Lars Komorowski, Nina van Beek, Michael P. Horn, Kai Fechner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Pemphigoid Pathology medicine.medical_specialty Adolescent Dermatology Immunofluorescence Desmoglein Autoimmune Diseases Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Pemphigoid Bullous medicine Humans Prospective Studies Child Fluorescent Antibody Technique Indirect education Aged Aged 80 and over education.field_of_study medicine.diagnostic_test business.industry Autoantibody Middle Aged medicine.disease 3. Good health Pemphigus Desmoglein 1 030220 oncology & carcinogenesis Desmoglein 3 Female Bullous pemphigoid business |
| Zdroj: | Journal of the American Academy of Dermatology. 83:1315-1322 |
| ISSN: | 0190-9622 |
| DOI: | 10.1016/j.jaad.2020.01.049 |
| Popis: | Background The current standard in the serologic diagnosis of autoimmune bullous diseases (AIBD) is a multistep procedure sequentially applying different assays. In contrast, the BIOCHIP Mosaic technology combines multiple substrates for parallel analysis by indirect immunofluorescence. Methods Sera from 749 consecutive, prospectively recruited patients with direct immunofluorescence–positive AIBD from 13 international study centers were analyzed independently and blinded by using (1) a BIOCHIP Mosaic including primate esophagus, salt-split skin, rat bladder, monkey liver, monkey liver with serosa, recombinant BP180 NC16A, and gliadin GAF3X, as well as HEK293 cells expressing recombinant desmoglein 1, desmoglein 3, type VII collagen, and BP230 C-terminus and (2) the conventional multistep approach of the Department of Dermatology, University of Lubeck. Results In 731 of 749 sera (97.6%), specific autoantibodies could be detected with the BIOCHIP Mosaic, similar to the conventional procedure (725 cases, 96.8%). The Cohen κ for both serologic approaches ranged from 0.84 to 1.00. In 6.5% of sera, differences between the 2 approaches occurred and were mainly attributed to autoantigen fragments not present on the BIOCHIP Mosaic. Limitations Laminin 332 and laminin γ1 are not represented on the BIOCHIP Mosaic. Conclusions The BIOCHIP Mosaic is a standardized time- and serum-saving approach that further facilitates the serologic diagnosis of AIBD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect